Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Just How Many Zombie Hayfever Drivers are on Britain’s Roads?
  • USA - English


News provided by

Medical Specialists® Pharmacy

May 25, 2016, 04:00 ET

Share this article

Share toX

Share this article

Share toX


Bury, Lancashire (PRWEB UK) 25 May 2016 -- Here at Medical Specialists® Pharmacy, we’d like to think that the majority of patients would not ever think of getting behind the wheel of a vehicle after consuming alcohol or after ingesting any illegal drugs.

However, how many would get behind the wheel after taking a few tablets of legal drugs? More specifically – over-the-counter or prescription medication.

A new survey by car insurance company Confused.com has found some alarming statistics which could highlight just how safety conscious some of the drivers on Britain’s roads actually are.

The survey showed that approximately 1 in every 15 motorists suffering with hayfever say that driving ability has been negatively impacted due to being under the influence of medication.

Post this

The survey showed that approximately 1 in every 15 motorists suffering with hayfever say that driving ability has been negatively impacted due to being under the influence of medication.

It is unclear in the Confused.com poll how many motorists were taking drowsy antihistamines and if any more sensibly decided to opt for the non-drowsy antihistamines before getting behind the wheel, the latter of which includes the popular loratadine and cetirizine, supplied from Medical Specialists®.

Antihistamine medicines are generally classified into three groups. These are:

  • First-generation antihistamines – These cause drowsiness in the majority of people and treatments include alimemazine, chlorphenamine, clemastine, cyproheptadine, diphenhydramine, hydroxyzine, ketotifen and promethazine. These medicines can also be used for their sedative effects should a person’s sleep be interrupted by itching.
  • Second- or third-generation antihistamines – These are referred to as ‘non-drowsy’ hayfever treatments as they are less likely to cause drowsiness, and include treatments such as acrivastine, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and mizolastine. However, those performing skilled tasks – for example, driving – should be aware that a sedative effect could occur and, in particular, in combination with alcohol.

Pharmacists or doctors would recommend taking second- or third-generation antihistamines and only first generation treatments where the sedating effects are beneficial to the person – i.e. to help them sleep.

The Confused.com poll found that 4% of those motorists reported they have been involved in a car accident following taking hay fever medication. This calls into question just how many sedated and zombie-like drivers are populating the roads, putting themselves at others at grave risk, especially with the survey revealing that more than 1 in 7 have driven after taking drugs.

These are not illegal drugs taken for a high – i.e. cocaine or ecstasy – the majority of those in the poll admit they are in fact driving while under the influence of legal prescription or over-the-counter medication. In fact, motorists are four times more likely to drive after taking a legal drug compared to an illegal one.

Although doses of prescribed or over-the-counter drugs might not be exceeding any limits with regards to driving, it seems those with hayfever are simply not paying attention to the important warnings given in the patient information leaflets. Medical Specialists® cannot stress enough how imperative it is to read these and they can contain warnings which could help to avoid illness or even death.

As mentioned previously, antihistamines are usually the first port of all for anyone looking to keep their hayfever symptoms at bay, but people may not realise that there can be dangerous and unpredictable effects if taken those with certain conditions or if taken in conjunction with other things such as alcohol or certain antidepressants. Failing to read the patient information leaflet to take the drugs only as directed would mean people would probably not realise these factors.

The Confused.com poll showed that 15% of motorists who suffer from hayfever do not bother to read the accompanying leaflet inside the medication’s box.

Furthermore, 1 in 15 Brits (7%) are not adhering to the recommended dose, whilst alarmingly, 3% admitted they were unaware there was such a thing.

There are about 16 million people in the UK that are suffering with hayfever, just over a third of motorists (34%) have the condition, with the majority taking medication to supress the symptoms that include watery and itchy eyes, a runny nose, sneezing and an itchy throat.

However, patients often forget that all prescription and over-the-counter drugs, which includes those to fight hayfever, can have some unwanted side effects.

The survey highlighted the common complaints from hayfever treatment, with the respondent’s driving ability affected by drowsiness (55%), feeling lethargic (35%) and blurred vision (35%).

Dr Richard Vautery, deputy chair of the British Medical Association General Practitioners Committee, said: “Patients have a responsibility to only drive if they feel safe to do so.

“If they feel any medication they are taking is adversely affecting their ability to make quick decisions or concentrate, then they shouldn’t be behind the wheel.

“Their insurance will also not be valid if they were to do so.

“Patients should discuss any new drugs they are prescribed with their GP and with the pharmacists that provides them to find out whether there would be any impact on their ability to drive.

“This information is also always within the leaflet provided to patients when they are given prescription drugs.”

In March last year, new drug-driving laws listing 8 prescription drugs and 8 illicit drugs came into force across England and Wales, with roadside drug screening devices to detect those driving under the influence.

The devices seem to be doing their job – in 2015, 2,090 motorists were charged with drug-driving, compared with just 870 in 2014 – an increase of 140% – according to Freedom of Information data.

Medical Specialists® again would like to stress the absolute importance of reading any drug’s patient information leaflet to avoid putting yourself and other’s at risk, especially whilst on the roads. As the weather is now picking up and more people are heading outdoors and into pollen-filled air, this means a lot of people with hayfever are going to suffer if they are not taking their antihistamines. In addition to reading through the safety information of any hayfever treatment, it is recommended everybody familiarises themselves with the drug-driving laws that came into force last year.

David Bailey, Medical Specialists® Pharmacy, http://www.medical-specialists.co.uk, +44 161 762 9108, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.